Barbara Altieri

List of Publications by Year
in descending order

92	1,821	279798	315739
papers	citations	23 h-index	38 g-index

104	104	104	2373
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors. Endocrine, 2022, 75, 623-634.	2.3	6
2	S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study. European Journal of Endocrinology, 2022, 186, 25-36.	3.7	41
3	Canine insulinoma as a model for human malignant insulinoma research: Novel perspectives for translational clinical studies. Translational Oncology, 2022, 15, 101269.	3.7	8
4	Sex differences in carcinoid syndrome: A gap to be closed. Reviews in Endocrine and Metabolic Disorders, 2022, 23, 659-669.	5.7	7
5	Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study. Lancet Diabetes and Endocrinology,the, 2022, 10, 499-508.	11.4	55
6	FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma. Endocrine, 2022, 77, 411-418.	2.3	6
7	From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 511-525.	5.7	13
8	Circulating microRNA Expression in Cushingâ€™s Syndrome. Frontiers in Endocrinology, 2021, 12, 620012.	3.5	11
9	Chronotype and cardio metabolic health in obesity: does nutrition matter?. International Journal of Food Sciences and Nutrition, 2021, 72, 892-900.	2.8	22
10	Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors. Frontiers in Endocrinology, 2021, 12, 649496.	3.5	27
11	Epithelial and Mesenchymal Markers in Adrenocortical Tissues: How Mesenchymal Are Adrenocortical Tissues?. Cancers, 2021, 13, 1736.	3.7	5
12	What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. Journal of Personalized Medicine, 2021, 11, 269.	2.5	14
13	Modified GRAS Score for Prognostic Classification of Adrenocortical Carcinoma: An ENSAT Multicentre Study. Journal of the Endocrine Society, 2021, 5, A165-A166.	0.2	1
14	Evaluation of the Molecular Pathogenesis of Adrenocortical Tumors by Whole-Genome Sequencing. Journal of the Endocrine Society, 2021, 5, A68-A68.	0.2	0
15	Case Report: Consecutive Adrenal Cushingâ€™s Syndrome and Cushingâ€™s Disease in a Patient With Somatic CTNNB1, USP8, and NR3C1 Mutations. Frontiers in Endocrinology, 2021, 12, 731579.	3.5	5
16	Management of Patients With Glucocorticoid-Related Diseases and COVID-19. Frontiers in Endocrinology, 2021, 12, 705214.	3.5	15
17	Identifying New Potential Biomarkers in Adrenocortical Tumors Based on mRNA Expression Data Using Machine Learning. Cancers, 2021, 13, 4671.	3.7	12
18	Clinical and penile Doppler outcomes using a modified, tourniquet free, Nesbit plication for severe Peyronieâ€™s disease. Translational Andrology and Urology, 2021, 10, 2857-2870.	1.4	0

#	Article	IF	Citations
19	The Importance of Being a â€˜Larkâ€™ in Post-Menopausal Women with Obesity: A Ploy to Prevent Type 2 Diabetes Mellitus?. Nutrients, 2021, 13, 3762.	4.1	17
20	Integrative genomic analysis reveals a conserved role for prolactin signalling in the regulation of adrenal function. Clinical and Translational Medicine, 2021, 11, e630.	4.0	4
21	A Multicenter Epidemiological Study on Second Malignancy in Non-Syndromic Pheochromocytoma/Paraganglioma Patients in Italy. Cancers, 2021, 13, 5831.	3.7	5
22	Mitotane treatment in adrenocortical carcinoma: mechanisms of action and predictive markers of response to therapy. Minerva Endocrinology, 2021, , .	1.1	2
23	Role of FGF Receptors and Their Pathways in Adrenocortical Tumors and Possible Therapeutic Implications. Frontiers in Endocrinology, 2021, 12, 795116.	3.5	2
24	Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 78-84.	3.6	39
25	Vitamin D testing: advantages and limits of the current assays. European Journal of Clinical Nutrition, 2020, 74, 231-247.	2.9	81
26	RNA Sequencing and Somatic Mutation Status of Adrenocortical Tumors: Novel Pathogenetic Insights. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4459-e4473.	3.6	24
27	Impact of the Chemokine Receptors CXCR4 and CXCR7 on Clinical Outcome in Adrenocortical Carcinoma. Frontiers in Endocrinology, 2020, 11, 597878.	3.5	18
28	Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma. Frontiers in Endocrinology, 2020, 11, 219.	3.5	23
29	Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. , 2020, 8, e000469.		59
30	Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. Endocrine, 2020, 69, 441-450.	2.3	26
31	Next-generation therapies for adrenocortical carcinoma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101434.	4.7	61
32	Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study. Cancers, 2020, 12, 359.	3.7	23
33	Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma. Cancers, 2020, 12, 740.	3.7	28
34	Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors. Nutrients, 2020, 12, 1021.	4.1	17
35	Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2642-2653.	3.6	18
36	ENDOCRINE TUMOURS: Calcitonin in thyroid and extra-thyroid neuroendocrine neoplasms: the two-faced Janus. European Journal of Endocrinology, 2020, 183, R197-R215.	3.7	14

#	Article	IF	Citations
37	Bone metabolism, bone mass and structural integrity profile in professional male football players. Journal of Sports Medicine and Physical Fitness, 2020, 60, 912-918.	0.7	5
38	SUN-LB22 PLK1 as a New Treatment Target for Adrenocortical Carcinoma. Journal of the Endocrine Society, 2020, 4, .	0.2	1
39	Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment. Journal of Clinical Medicine, 2019, 8, 1850.	2.4	31
40	Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management. Cancers, 2019, 11, 1332.	3.7	28
41	Nutritionist and obesity: brief overview on efficacy, safety, and drug interactions of the main weight-loss dietary supplements. International Journal of Obesity Supplements, 2019, 9, 32-49.	12.6	24
42	Patient empowerment and the Mediterranean diet as a possible tool to tackle prediabetes associated with overweight or obesity: a pilot study. Hormones, 2019, 18, 75-84.	1.9	37
43	Calcium and Vitamin D Supplementation. Myths and Realities with Regard to Cardiovascular Risk. Current Vascular Pharmacology, 2019, 17, 610-617.	1.7	22
44	SUN-350 Sterol-O-Acyl Transferase 1 Protein Expression Alone Is Not Sufficient to Predict Response to Mitotane Treatment in Adrenocortical Carcinoma. Journal of the Endocrine Society, 2019, 3, .	0.2	0
45	ERCC1 as predictive biomarker to platinum-based chemotherapy in adrenocortical carcinomas. European Journal of Endocrinology, 2018, 178, 181-188.	3.7	15
46	Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4511-4523.	3.6	92
47	An Italian Survey of Compliance With Major Guidelines for L-Thyroxine of Primary Hypothyroidism. Endocrine Practice, 2018, 24, 419-428.	2.1	13
48	Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness. Nutrients, 2018, 10, 1854.	4.1	61
49	Nutrition and neuroendocrine tumors: An update of the literature. Reviews in Endocrine and Metabolic Disorders, 2018, 19, 159-167.	5.7	38
50	Adrenocortical incidentalomas and bone: from molecular insights to clinical perspectives. Endocrine, 2018, 62, 506-516.	2.3	11
51	The role of insulin-like growth factor system in the adrenocortical tumors. Minerva Endocrinologica, 2018, 44, 43-57.	1.8	25
52	Vitamin D and pancreas: The role of sunshine vitamin in the pathogenesis of diabetes mellitus and pancreatic cancer. Critical Reviews in Food Science and Nutrition, 2017, 57, 3472-3488.	10.3	77
53	Shedding new light on female fertility: The role of vitamin D. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 273-283.	5.7	98
54	Does vitamin D play a role in autoimmune endocrine disorders? A proof of concept. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 335-346.	5.7	134

#	Article	IF	Citations
55	Current evidence on vitamin D deficiency and kidney transplant: Whatâ€™s new?. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 323-334.	5.7	15
56	Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4323-4332.	3.6	79
57	Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3491-3498.	3.6	33
58	Adrenal disorders: Is there Any role for vitamin D?. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 355-362.	5.7	17
59	Vitamin D and chronic diseases: the current state of the art. Archives of Toxicology, 2017, 91, 97-107.	4.2	108
60	Livin/BIRC7 expression as malignancy marker in adrenocortical tumors. Oncotarget, 2017, 8, 9323-9338.	1.8	27
61	Leydig Cell Tumour and Giant Adrenal Myelolipoma Associated with Adrenogenital Syndrome: A Case Report with a Review of the Literature. Urologia, 2016, 83, 43-48.	0.7	6
62	Adrenocortical tumors and insulin resistance: What is the first step?. International Journal of Cancer, 2016, 138, 2785-2794.	5.1	29
63	Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome. Endocrine-Related Cancer, 2015, 22, 531-543.	3.1	27
64	CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma. PLoS ONE, 2014, 9, e105855.	2.5	41
65	Chronic low-dose glucocorticoid inhalatory therapy as a cause of bone loss in a young man: case report. Clinical Cases in Mineral and Bone Metabolism, 2013, 10, 199-202.	1.0	6
66	Low bone mineral density in a growth hormone deficient (GHD) adolescent. Clinical Cases in Mineral and Bone Metabolism, 2013, 10, 203-5.	1.0	5
67	Adverse events of mitotane treatment in patients with adrenocortical carcinoma. Endocrine Abstracts, 0, , .	0.0	0
68	Circulating cell-free DNA for prognostication and disease surveillance in adrenocortical carcinoma. Endocrine Abstracts, 0, , .	0.0	0
69	Targeted molecular analysis in adrenocortical carcinomas: a strategy towards improved personalized prognostication. Endocrine Abstracts, 0, , .	0.0	2
70	Cytochrome P450 (CYP) 2W1 affect steroid secretion in adrenocortical cell line and tumor tissues. Endocrine Abstracts, 0, , .	0.0	1
71	The Notch ligand Jagged1 is up-regulated in adrenocortical carcinomas and is associated with a favourable clinical outcome. Endocrine Abstracts, 0, , .	0.0	0
72	Inhibitor of apoptosis protein livin/BIRC7 in adrenocortical tumours. Endocrine Abstracts, 0, , .	0.0	0

#	Article	IF	Citations
73	CYP2W1*6 polymorphism as a potential predictive marker of sensitivity to mitotane treatment in adrenocortical carcinoma.. Endocrine Abstracts, 0, , .	0.0	0
74	Epithelial to mesenchymal transition in adrenocortical tumours: focus on FGF-FGFR pathway and c-MET. Endocrine Abstracts, 0, , .	0.0	0
75	Germline CYP2W1*6 polymorphism is a new predictive marker of sensitivity to mitotane treatment in advanced adrenocortical carcinoma: a multicenter European study. Endocrine Abstracts, 0, , .	0.0	0
76	Mesenchymal tissue markers as potential drug targets in adrenocortical tumours. Endocrine Abstracts, 0, , .	0.0	0
77	Targeted molecular analysis in adrenocortical carcinomas: a way towards improved personalized prognostication. Endocrine Abstracts, 0, , .	0.0	1
78	New cancer drug targets identified in adrenocortical carcinoma through gene expression profiling. Endocrine Abstracts, 0, , .	0.0	1
79	Germline CYP2W1*6 and CYP2B6*6 polymorphisms as predicting markers of sensitivity to mitotane treatment in advanced adrenocortical carcinoma: a multicentric ENSAT study. Endocrine Abstracts, 0, , .	0.0	0
80	Cyclin dependent kinase 4 as promising drug target in adrenocortical carcinoma. Endocrine Abstracts, 0, , .	0.0	0
81	Neuroendocrine neoplasms (NEN) arising in uncommon sites: epidemiological and clinical features. Endocrine Abstracts, 0, , .	0.0	0
82	Management of adjuvant mitotane therapy for adrenocortical carcinoma: a survey in Italy. Endocrine Abstracts, 0, , .	0.0	0
83	Vitamin D deficiency is a predictor marker of tumor aggressiveness in sporadic and MEN1-related well-differentiated, low-grade GEP-NET. Endocrine Abstracts, 0, , .	0.0	0
84	Lanreotide therapy vs wait-and-see in patients with pancreatic neuroendocrine tumors. Endocrine Abstracts, 0, , .	0.0	1
85	PLK1 inhibitors as potential new treatment for adrenocortical carcinoma. Endocrine Abstracts, 0, , .	0.0	0
86	Sporadic neuroendocrine neoplasms in young-adult patients: Differences in natural history, prognosis and treatment compared to adult-elderly patients. Endocrine Abstracts, 0, , .	0.0	0
87	Modified GRAS score for prognostic classification of adrenocortical carcinoma: an ENSAT multicentre study. Endocrine Abstracts, 0, , .	0.0	0
88	RNA-sequencing of adrenocortical tumors reveals novel pathogenetic insights. Endocrine Abstracts, 0, , .	0.0	1
89	Adverse events associated to mitotane treatment in patients with adrenocortical carcinoma. Endocrine Abstracts, 0, , .	0.0	0
90	Consecutive adrenal cushingÂ´s syndrome and cushingÂ´s disease in a patient with somatic CTNNB1, USP8, and NR3c1 mutations. Endocrine Abstracts, 0, , .	0.0	0

#	Article	IF	Citations
91	PLK1 inhibitors as a new targeted treatment for adrenocortical carcinoma. Endocrine Abstracts, 0, , .	0.0	0
92	Circulating cell-free DNA-based biomarkers as a tool for disease surveillance in adrenocortical carcinoma. Endocrine Abstracts, 0, , .	0.0	0